Skip to main content

The Eyes Have It! Why Regeneron Is Hitting A 52-Week High

An experimental eye drug from Novartis looks to be a threat to Regeneron's blockbuster drug Eylea. Yet Regeneron's share price is spiking today, and this analyst sees it climbing even higher. Here's why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.